EQT AB FY25 Net Income Down On Weak Revenues; EBITDA, Margin Rise; To Buy Coller Capital

EQT reported mixed fiscal 2025 results with net income down to €728m (from €776m) and EPS of €0.618 (vs €0.656), while adjusted net income rose to €1.32bn (from €1.12bn) and adjusted EPS to €1.122 (from €0.942). EBITDA increased to €1.38bn with margin improving to 52% (from 50%), adjusted EBITDA €1.64bn (60% margin), and total revenue slightly fell to €2.63bn (from €2.65bn) while adjusted revenue rose to €2.73bn. The board proposed a higher dividend of SEK 5.00 (vs 4.30) to be paid in two installments in May and December 2026. EQT also agreed to acquire secondaries firm Coller Capital for $3.2bn paid in newly issued EQT shares (plus up to $500m contingent cash), a deal expected to be mid-single-digit accretive to fee-related earnings.

Analysis

Market structure: EQT's announced €3.2bn share‑funded acquisition of Coller Capital (plus up to $500m cash contingent) consolidates scale in secondaries and should lift recurring fee‑related earnings (management says mid‑single‑digit accretion). Direct winners: EQT shareholders if integration drives cross‑selling and fee margin expansion; sellers of boutique secondaries may lose talent/market share. Supply/demand: larger aggregated secondary inventory and fundraising scale could improve pricing power for GPs buying secondaries and tighten spreads for sellers over 12–36 months.

Risk assessment: Immediate risks (days) are equity price reaction to the share issue and investor dilution; short term (weeks–months) risks are deal approval, integration, and up to $500m cash payout tied to earn‑outs; long term (12–36 months) risks include NAV marks, underperformance of Coller assets or regulatory/competition scrutiny. Tail scenarios: activist pushback, material goodwill writedowns >€300–500m, or a slow private markets cycle that erodes expected accretion. Hidden dependency: fee acceleration depends on secondary market volume and exit valuations, not just headline EBITDA.

Trade implications: Favor a modest pro‑risk stance on EQT.ST while hedging GP beta. Tactically buy equity or call spreads to capture a 12‑month re‑rating if fee‑related earnings + dividend (SEK5.00) are realized; hedge via short positions in global alternative asset managers (KKR, KKR; Blackstone, BX) to isolate company‑specific upside. Options: buy 6–9 month call spreads to limit premium outlay; avoid levering into potential short‑term dilution until shareholder approval is confirmed.

Contrarian angles: The market may overweight GAAP net income drop and miss adjusted EBITDA/margin gains (adjusted EBITDA +20% YoY to €1.64bn). Issuing equity to buy Coller is conservatively capitalized versus debt financing — an underappreciated de‑risk for bond holders and credit spreads. Historical parallels: large GP acquisitions (e.g., Strategic Partners deals) often re‑rate after 12–18 months if performance fees materialize; a >10% post‑deal selloff should be treated as a buying opportunity.

Key Decisions for Investors

• Establish a 2–3% long position in EQT AB (EQT.ST) within 2–4 weeks targeting a 12‑month horizon and +20–30% upside; set an initial hard stop at –18% and trim into +15% gains.
• Construct a hedged options trade: buy a 9‑month EQT.ST call spread (long ~15% OTM call, short ~45% OTM call) sized to cover 50–75% of the equity position to cap cost while retaining upside to a potential re‑rating.
• Enter a relative value pair: long EQT.ST (2% portfolio) vs short KKR (KKR) or Blackstone (BX) (net short notional ~50% of long) to isolate EQT‑specific accretion; rebalance if spread moves >10% within 90 days.
• Do not add beyond 3% position until shareholder approval and deal financing details confirmed (monitor announcement timeline and any disclosure of contingent consideration metrics within 30–60 days); if management confirms >5% fee‑related earnings accretion and leverage unchanged, scale to 4–6%.
• If EQT shares drop >10% post‑announcement (sell‑off on dilution fears), incrementally accumulate to reach 4% position; if EQT prints a >€300m goodwill or NAV impairment, cut exposure to <=1% and reassess fundamentals.